A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
Inclusion Criteria:
1) Target Population: Subject has at least 1 year history of episodic migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:
Exclusion Criteria:
Sex and Reproductive Status:
Prohibited Medications:
Westerstede, Lower Saxony 26655, Germany
Rome, Lazio 00189, Italy
Bologna, 40139, Italy
Wroclaw, Lower Silesian Voivodeship 52-210, Poland
Lublin, Lublin Voivodeship 20-582, Poland
Chesterfield, Derbyshire S40 4AA, United Kingdom